Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of a Single Subcutaneous Dose of IMG-007 in Healthy Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Carina Freedman
- Phone Number: 18583456927
- Email: freedmanc@inmagenebio.com
Study Locations
-
-
-
Perth, Australia
- Linear Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Body mass index (BMI) greater than or equal to 18.0 kg/m2 and less than or equal to 32 kg/m2, and a minimum body weight of 50 kg for males and 45 kg for females
- Able to participate and comply with all study procedures and restrictions, and willing to provide written informed consent to participate in the study.
- Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions: not of childbearing potential or of childbearing potential and agrees to use a highly effective method of contraception.
- Male participants who agree to practice true abstinence or agree to use highly effective methods of contraception with female partners of childbearing potentials or are surgically sterilized.
Exclusion Criteria:
- Conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study.
- Major surgery ≤ 4 weeks before the Baseline Visit or planned major surgical procedure during the study.
- Use of any prescription medication (except for hormonal contraceptives for female participants within the 14 days prior to the first dose.
- Drug or alcohol abuse.
- Use of more than 5 tobacco/nicotine-containing products per month within 3 months of the first dose.
- Hepatitis B, hepatitis C, or human immunodeficiency virus infection.
- Evidence of latent tuberculosis (TB) or a history of untreated or inadequately treated TB infection.
- Receipt of a live/live attenuated vaccine within 2 months prior to Baseline Visit.
- Hypersensitivity to study treatment or other biologics
- Participation in prior IMG-007 study or another research study involving an investigational product within 30 days (small molecule) or 3 months (biological product), or 5 half-lives (whichever is longer) prior to the Baseline (Day 1) Visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: IMG-007 Cohort 1 (Healthy Participant)
Cohort 1 will receive a single subcutaneous dose of IMG-007 Dose 1 or matching placebo.
|
Subcutaneous injection of IMG-007
Subcutaneous Injection of Placebo
|
|
Experimental: IMG-007 Cohort 2 (Healthy Participant)
Cohort 2 will receive a single subcutaneous dose of IMG-007 Dose 2 or matching placebo.
|
Subcutaneous injection of IMG-007
Subcutaneous Injection of Placebo
|
|
Experimental: IMG-007 Cohort 3 (Healthy Participant)
Cohort 3 will receive a single subcutaneous dose of IMG-007 Dose 3 or matching placebo.
|
Subcutaneous injection of IMG-007
Subcutaneous Injection of Placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Event Evaluation
Time Frame: Up to 18 weeks
|
Incidence of adverse events emergent from a single subcutaneous dose of IMG-007 in healthy participants.
|
Up to 18 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetic Parameters, Cmax
Time Frame: Up to 18 weeks
|
Peak serum concentration following the administration of a single subcutaneous dose of IMG-007
|
Up to 18 weeks
|
|
Pharmacokinetic Parameters, Tmax
Time Frame: Up to 18 weeks
|
Time to peak serum concentration following the administration of a single subcutaneous dose of IMG-007
|
Up to 18 weeks
|
|
Pharmacokinetic Parameters, AUC0-t
Time Frame: Up to 18 weeks
|
Area under the concentration-time curve from time 0 until the last observed concentration following the administration of a single subcutaneous dose of IMG-007
|
Up to 18 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- IMG-007-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.